Financial Data and Key Metrics Changes - Omeros reported a net income of $86.5 million or $1.22 per share for Q4 2025, a significant improvement from a net loss of $30.9 million or $0.47 per share in Q3 2025 [15][21] - The fourth quarter results included a net gain of $237.6 million from the sale of zaltenibart to Novo Nordisk [15][25] - Excluding a $136 million non-cash charge related to embedded derivatives, the non-GAAP adjusted net income was $222.5 million, translating to $3.14 per share [16][22] Business Line Data and Key Metrics Changes - The zaltenibart transaction with Novo Nordisk provided Omeros with an upfront cash payment of $240 million and potential milestone payments totaling up to $2.1 billion [5][6] - YARTEMLEA, the first approved treatment for TA-TMA, has begun commercial sales, with initial pricing set at approximately $36,000 per vial [10][12] Market Data and Key Metrics Changes - Omeros is focusing on the top 80 transplant centers in the U.S., which account for about 80% of annual stem cell transplants [10][11] - The company has achieved P&T committee approvals for YARTEMLEA at 50% of the top 10 U.S. transplant centers and is actively working to expand this coverage [12][34] Company Strategy and Development Direction - The company aims to achieve financial self-sustainability through the YARTEMLEA program in 2026 and expects to reach positive cash flow by 2027 [17][29] - Omeros is exploring additional indications for YARTEMLEA, including ARDS and solid organ transplant-related TMA, while also advancing its MASP-2 antibody and small molecule programs [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing demand for YARTEMLEA, highlighting the urgency for treatment in transplant patients [35][49] - The company anticipates continued progress in P&T committee approvals and is optimistic about the reception of YARTEMLEA in the market [33][34] Other Important Information - Omeros has eliminated all indebtedness under its senior secured term loan and 2026 notes, leaving only $70.8 million in convertible notes due in 2029 [17][24] - The company is also advancing its TCAT platform for pathogen-targeting therapies, addressing the growing threat of multidrug-resistant organisms [18][19] Q&A Session Summary Question: Progress of formulary additions across transplant centers - Management is pleased with the speed of P&T committee approvals and expects continued progress throughout the year [33][34] Question: Real-world vial usage of YARTEMLEA - Initial usage shows a split of approximately 70% once weekly and 30% twice weekly, with expectations for a shift towards more frequent dosing as education efforts continue [37][38] Question: Financial sustainability and cash flow - The company aims for YARTEMLEA to be self-sustaining in 2026, with positive cash flow expected by 2027 [42][43] Question: Feedback from sales force on formulary allowance - The sales team reports positive responses from medical centers, with a strong recognition of the urgency for YARTEMLEA [45][47] Question: EMA decision and partnership discussions - The focus remains on achieving EMA approval for YARTEMLEA, with high interest noted at recent industry meetings [51][52] Question: Access to YARTEMLEA and patient starts - All requests for access to YARTEMLEA have been granted, with a mix of medical exceptions and formal formulary coverage [70][74]

Core Insights - Omeros Corporation has secured a significant deal with Novo Nordisk valued at approximately $2.1 billion for its phase 2 asset, zaltenibart, aimed at treating rare blood and kidney disorders [2] - Analysts on Wall Street are optimistic about Omeros, with HC Wainwright assigning a Buy rating and a price target of $9 for the company's shares [3] Company Overview - Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics, particularly for orphan indications targeting immunologic diseases [4] Product Pipeline - The lead product candidate of Omeros is Narsoplimab, which is being developed for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy [3] - Omeros is also developing OMS1029, which has successfully completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 and lectin pathway disorders [3]

Core Points - Omeros Corporation will announce its financial results for Q3 2025 on November 13, 2025, after market close [1] - A conference call and webcast will be held on the same day at 4:30 p.m. Eastern Time to discuss the results and recent developments [1] Company Overview - Omeros is a clinical-stage biopharmaceutical company focused on developing therapeutics for complement-mediated diseases, cancers, and addictive disorders [5] - The lead product, narsoplimab, is under regulatory review for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy [5] - OMS1029, a long-acting MASP-2 inhibitor, has completed Phase 1 clinical trials, while zaltenibart (OMS906) is in development for PNH and C3 glomerulopathy [5] - Novo Nordisk has acquired global rights to zaltenibart, including associated intellectual property [5] - Omeros' pipeline includes OMS527, a phosphodiesterase 7 inhibitor for cocaine use disorder, funded by the National Institute on Drug Abuse [5]

Financial Data and Key Metrics Changes - The company reported a net loss of $33.5 million or $0.58 per share for the first quarter of 2025, compared to a net loss of $31.4 million or $0.54 per share in the fourth quarter of the previous year [5][19] - As of March 31, 2025, the company had $52.5 million in cash and investments on hand [5][19] - The company has reduced its total outstanding debt by $10 million and lowered its near-term repayment obligations from approximately $118 million to $17 million [6][20] Business Line Data and Key Metrics Changes - Research and development expenses in the first quarter were heavily focused on narsoplimab and zaltanibart [21] - OMIDRIA royalties for the first quarter totaled $6.7 million based on net sales of $22.3 million, a decrease from $10.1 million in royalties on net sales of $33.6 million in the previous quarter [23][24] Market Data and Key Metrics Changes - The market opportunity for narsoplimab is estimated at nearly $1 billion annually, with expectations for it to become a cornerstone asset for transplant experts [12] - The global market for paroxysmal nocturnal hemoglobinuria (PNH) is projected to grow about 11% annually to over $10 billion by 2032 [13] Company Strategy and Development Direction - The company is focused on the successful launch of narsoplimab for the treatment of TATMA, following the anticipated FDA approval [8][9] - The company is also developing zaltanibart, targeting PNH, while managing costs and pausing certain programs to prioritize resources [14][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming launch of narsoplimab, highlighting the preparation and engagement with key transplant centers and payers [35][36] - The company is committed to managing cash and liquidity effectively to support operations and capitalize on growth opportunities [7][49] Other Important Information - The FDA has accepted the resubmitted BLA for narsoplimab, with a target action date of September 25 [9] - The company is also working on a marketing authorization application for narsoplimab in Europe, targeting submission later this quarter [10] Q&A Session Summary Question: Can you provide details on launch plans and patient access? - Management indicated that the commercial team is well-prepared for the launch, focusing on key transplant centers and engaging with payers for product information exchanges [30][31][35] Question: Can you elaborate on the patients affected by TATMA and associated costs? - Management explained that TATMA is a complication of stem cell transplants that can arise unpredictably, leading to significant healthcare costs due to the severity of the condition [38][44] - The economic value of narsoplimab is highlighted by its potential to reduce costs associated with untreated patients, emphasizing outpatient treatment benefits [46][47]